These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 577507)

  • 1. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
    Assinder DF; Chasseaud LF; Taylor T
    J Pharm Sci; 1977 Jun; 66(6):775-8. PubMed ID: 577507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.
    Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T
    Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations.
    Chasseaud LF; Darragh A; Doyle E; Lambe RF; Taylor T
    J Pharm Sci; 1984 May; 73(5):699-701. PubMed ID: 6737249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects.
    Mansel-Jones D; Taylor T; Doyle E; Chasseaud LF; Darragh A; O'Kelly DA; Over H
    J Clin Pharmacol; 1978; 18(11-12):544-8. PubMed ID: 721951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation.
    Chasseaud LF; Doyle E; Taylor T; Darragh A
    Biopharm Drug Dispos; 1981; 2(3):273-81. PubMed ID: 7295884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects.
    Taylor T; O'Kelly DA; Major RM; Darragh A; Chasseaud LF
    Arzneimittelforschung; 1978; 28(8):1426-8. PubMed ID: 582411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isosorbide dinitrate bioavailability, kinetics, and metabolism.
    Straehl P; Galeazzi RL
    Clin Pharmacol Ther; 1985 Aug; 38(2):140-9. PubMed ID: 4017416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.
    Halkin H; Almog S; Friedman E
    Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state.
    Taylor T; Chasseaud LF; Major RM; Leaf FC; Bonn R; Darragh A; Lambe RF
    Biopharm Drug Dispos; 1985; 6(2):119-29. PubMed ID: 4005392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
    Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
    Muck B; Bonn R; Rietbrock N
    Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
    Laufen H; Leitold M; Wildfeuer A
    Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
    Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF
    Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bioavailability of delayed-action and non-delayed-action preparations of isosorbide-5-nitrate].
    Heidemann R; Gracien E; Menke G; Rietbrock N
    Dtsch Med Wochenschr; 1987 May; 112(18):719-22. PubMed ID: 3569063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of isosorbide dinitrate saliva concentrations for biopharmaceutical investigations.
    Laufen H; Schmid M; Leitold M
    J Pharm Sci; 1983 May; 72(5):496-9. PubMed ID: 6864494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)].
    Kogi K; Chida S; Kimura T; Saito T
    Nihon Yakurigaku Zasshi; 1980 Mar; 76(2):99-107. PubMed ID: 7399370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
    Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
    Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative determination of isosorbide dinitrate and two metabolites in plasma.
    Chin DA; Prue DG; Michelucci J; Kho BT; Warner CR
    J Pharm Sci; 1977 Aug; 66(8):1143-5. PubMed ID: 894502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
    Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
    Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects.
    Taylor T; Chasseaud LF; Doyle E; Darragh A; O'Kelly DA; Fitzgerald D
    Biopharm Drug Dispos; 1980; 1(3):149-56. PubMed ID: 7448342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.